Neu-001 for the treatment of amblyopia

Amblyopia ("lazy eye") affects 3–6% of the population worldwide. While early intervention through eye patching shows some success in young children, there are currently no effective pharmacological treatments available, particularly for adults. This represents a significant unmet medical need.

• A first-in-class small molecule therapeutic targeting GPCR in the visual cortex, representing a paradigm shift from traditional eye-focused treatments for amblyopia.
• Novel mechanism of action enables the treatment of adult amblyopia, a condition previously considered untreatable due to limited brain plasticity.
• This unique therapeutic strategy offers a potential pharmacological solution for both pediatric and adult patients, addressing a significant gap in current treatment options.

• It has a potential to provide the first pharmaceutical cure for amblyopia, dramatically improving treatment efficiency and outcomes compared to current standard of care.
• Expands treatment opportunity to adult patients previously considered untreatable, addressing an unmet medical need for tens of millions globally.
• It improves patient compliance and quality of life through convenient pharmaceutical administration, compared to traditional mechanical interventions.
• It offers significant healthcare economic benefits by reducing long-term complications and improving treatment efficiency.

• Primary treatment for newly diagnosed amblyopia in children
• Treatment for adult amblyopia patients previously considered untreatable